Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 647 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: rapamycin Clear all
Completed Phase 1 Interventional

Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

NCT01548807
View directory record Official record
Conditions
Prostate Cancer Patients With Detectable PSA Following Prostatectomy
Interventions
Everolimus (RAD001)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Oct 19, 2026, 6:33 PM EDT
Enrolling by invitation Phase 2 Interventional

Sirolimus for Leigh Syndrome

NCT06843811
View directory record Official record
Conditions
Leigh Syndrome
Interventions
Sirolimus
Drug
Lead sponsor
Matthew Demczko
Other
Eligibility
6 Months to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)

NCT06682767
View directory record Official record
Conditions
Cerebral Blood Flow, APOE 4
Interventions
FMD1 (LNT22-017-1), Rapamycin, Placebo
Dietary Supplement · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
45 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)

NCT03333694
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma in Situ (CSCCis)
Interventions
Cutaneous Cream application, Placebo Cutaneous Cream application
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Phoenix, Arizona • Fountain Valley, California • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 19, 2026, 6:33 PM EDT
Withdrawn Phase 1 Interventional

Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis

NCT02528877
View directory record Official record
Conditions
Acute Myeloid Leukemia in Remission, Primary Myelofibrosis, Primary Myelofibrosis, Prefibrotic Stage, Secondary Acute Myeloid Leukemia, Secondary Myelofibrosis
Interventions
Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Ruxolitinib Phosphate, Sirolimus, Tacrolimus
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 19, 2026, 6:33 PM EDT
Terminated Phase 4 Interventional Results available

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

NCT00166712
View directory record Official record
Conditions
Kidney Transplant Failure and Rejection
Interventions
Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Oct 19, 2026, 6:33 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage

NCT07662174
View directory record Official record
Conditions
Post-hemorrhagic Hydrocephalus (PHH)
Interventions
Sirolimus (Rapamune®)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Not applicable Interventional

Calcineurin Inhibitor Based Immunosuppression Withdrawal

NCT02117596
View directory record Official record
Conditions
Renal Transplant
Interventions
Sirolimus
Drug
Lead sponsor
Pediatric Nephrology of Alabama
Other
Eligibility
Up to 19 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 19, 2026, 6:33 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations

NCT06653842
View directory record Official record
Conditions
Cutaneous Venous Malformations
Interventions
QTORIN 3.9% rapamycin anhydrous gel
Drug
Lead sponsor
Palvella Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Irvine, California • Palo Alto, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

NCT00533442
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Rapamycin, Mycophenolate Mofetil, Tacrolimus, Steroids
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional

Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors

NCT01072890
View directory record Official record
Conditions
Solid Tumors
Interventions
Temsirolimus, Pazopanib
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Oct 19, 2026, 6:33 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Danvatirsen, Ceralasertib, Vistusertib, Olaparib, Oleclumab, Trastuzumab deruxtecan, Cediranib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
17
States / cities
Duarte, California • Fullerton, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

NCT02891603
View directory record Official record
Conditions
Graft Vs Host Disease, GVHD
Interventions
Pacritinib, Sirolimus, Tacrolimus, Allogenic hematopoietic cell transplant (alloHCT)
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Terminated Phase 2 Interventional Results available

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

NCT01420081
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
PF-05212384
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
21
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 19, 2026, 6:33 PM EDT
Terminated Phase 2 Interventional Results available

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

NCT02031536
View directory record Official record
Conditions
Gastrinoma, Glucagonoma, Insulinoma, Liver Metastases, Pancreatic Polypeptide Tumor, Recurrent Islet Cell Carcinoma, Somatostatinoma
Interventions
everolimus, placebo
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional

Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours

NCT01135563
View directory record Official record
Conditions
Solid Tumors, Central Nervous System Tumors
Interventions
Vinblastine and Sirolimus
Drug
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
Up to 21 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
San Diego, California • St Louis, Missouri • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available

Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma

NCT01016015
View directory record Official record
Conditions
Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Osteosarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
22
States / cities
Los Angeles, California • Jacksonville, Florida • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1 Interventional Results available

A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

NCT00927823
View directory record Official record
Conditions
Cancer
Interventions
PF-04691502
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
7
States / cities
Los Angeles, California • Santa Monica, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

NCT01938573
View directory record Official record
Conditions
Recurrent Bladder Carcinoma, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
Interventions
Cisplatin, Gemcitabine Hydrochloride, Sirolimus, Cystectomy
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

NCT03433183
View directory record Official record
Conditions
Malignant Peripheral Nerve Sheath Tumors, Neurofibromatosis 1
Interventions
Selumetinib, Sirolimus
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Feasibility of [11C]Acetate-PET in LAM and TSC

NCT05467397
View directory record Official record
Conditions
Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Interventions
[11C]acetate
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection

NCT00006178
View directory record Official record
Conditions
Kidney Failure
Interventions
Sirolimus, Thymoglobulin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 19, 2026, 6:33 PM EDT
Withdrawn Phase 2 Interventional

Sirolimus Prophylaxis for aGVHD in TME SCID

NCT02177760
View directory record Official record
Conditions
Severe Combined Immunodeficiency, Transplacental Maternal Engraftment, Stem Cell Transplant
Interventions
Sirolimus
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Day to 1 Year
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 19, 2026, 6:33 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer

NCT00522665
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Irinotecan, Cetuximab, RAD001
Drug · Biological
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
14
States / cities
Chicago, Illinois • Galesburg, Illinois • Bloomington, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 19, 2026, 6:33 PM EDT